158 related articles for article (PubMed ID: 10449288)
21. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
[TBL] [Abstract][Full Text] [Related]
22. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.
Friedl AC; Ledergerber B; Flepp M; Hirschel B; Telenti A; Furrer H; Bucher HC; Bernasconi E; Weber R;
AIDS; 2001 Sep; 15(14):1793-800. PubMed ID: 11579241
[TBL] [Abstract][Full Text] [Related]
23. Virological response to protease inhibitor therapy in an HIV clinic cohort.
Staszewski S; Miller V; Sabin C; Carlebach A; Berger AM; Weidmann E; Helm EB; Hill A; Phillips A
AIDS; 1999 Feb; 13(3):367-73. PubMed ID: 10199227
[TBL] [Abstract][Full Text] [Related]
24. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
[TBL] [Abstract][Full Text] [Related]
25. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level.
Viard JP; Burgard M; Hubert JB; Aaron L; Rabian C; Pertuiset N; Lourenço M; Rothschild C; Rouzioux C
AIDS; 2004 Jan; 18(1):45-9. PubMed ID: 15090828
[TBL] [Abstract][Full Text] [Related]
26. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.
Kosmiski LA; Kuritzkes DR; Lichtenstein KA; Glueck DH; Gourley PJ; Stamm ER; Scherzinger AL; Eckel RH
AIDS; 2001 Oct; 15(15):1993-2000. PubMed ID: 11600828
[TBL] [Abstract][Full Text] [Related]
27. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India.
Banerjee T; Pensi T; Banerjee D; Grover G
Ann Trop Paediatr; 2010; 30(1):27-37. PubMed ID: 20196931
[TBL] [Abstract][Full Text] [Related]
28. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients.
Langford D; Marquie-Beck J; de Almeida S; Lazzaretto D; Letendre S; Grant I; McCutchan JA; Masliah E; Ellis RJ
J Neurovirol; 2006 Apr; 12(2):100-7. PubMed ID: 16798671
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
30. Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy.
Sabin CA; Yee TT; Devereux H; Griffioen A; Loveday C; Phillips AN; Lee CA
AIDS; 2000 May; 14(8):1001-7. PubMed ID: 10853982
[TBL] [Abstract][Full Text] [Related]
31. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
Powles T; Imami N; Nelson M; Gazzard BG; Bower M
AIDS; 2002 Mar; 16(4):531-6. PubMed ID: 11872995
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.
DeSimone JA; Pomerantz RJ; Babinchak TJ
Ann Intern Med; 2000 Sep; 133(6):447-54. PubMed ID: 10975963
[TBL] [Abstract][Full Text] [Related]
33. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
[TBL] [Abstract][Full Text] [Related]
34. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
35. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
[No Abstract] [Full Text] [Related]
36. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA).
Thiébaut R; Morlat P; Jacqmin-Gadda H; Neau D; Mercié P; Dabis F; Chêne G
AIDS; 2000 May; 14(8):971-8. PubMed ID: 10853978
[TBL] [Abstract][Full Text] [Related]
37. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
[TBL] [Abstract][Full Text] [Related]
38. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
[TBL] [Abstract][Full Text] [Related]
39. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
40. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]